Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων
Real-life experience in Spain (Spanish Group of Lymphoma and
Bone Marrow Transplantation, GELTAMO). Efficacy and
safety of nivolumab in real-life for the treatment of R/R Hodgkin
lymphoma is comparable with that reported in clinical trials.·The
main reasons for nivolumab discontinuation were referral for
transplantation and disease...
In a cohort of 126 allogeneic HCT recipients transplanted 1-39
years ago,62% were seropositive/seroprotected for measles before
any vaccination since transplantation. The
seropositivity/seroprotection was associated with
myeloproliferative disorder, reduced intensity or non-myeloablative
conditioning and absence of acute grade>2 graft-versus-host
disease.·Our findings strongly support a systematic assessment...
Presenter: Dr Liga,
Participants: Prof.Spyridonidis, Dr Tsokanas, Dr Lekka, Dr
Bali
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
A review on a very common complication in our
patients.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr
Bali
Which aml sr pts benefit from transplant. Another role of
mrd.
https://pubmed.ncbi.nlm.nih.gov/29601212/?dopt=Abstract
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
https://pubmed.ncbi.nlm.nih.gov/33897681/
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2020010543/476241/CAR-HEMATOTOX-A-model-for-CAR-T-cell-related?redirectedFrom=fulltext
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
With a limited follow-up, the German experience (203 pts)
with SOC
CAR-T cells in LBCL is in keeping with the approval trials in
terms of
safety, whereas our efficacy data appear to be inferior to
published
results.
ABSTRACT EBMT
AA2-2 STANDARD-OF-CARE CAR-T CELL THERAPY FOR LARGE B-CELL
LYMPHOMA:
REAL WORLD...
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Presenter: Dr Liga
Participants: Prof.Spyridonidis, Dr Tsokanas, Dr Lekka
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Excellent review on HMA, their clinical use and
mechnisms on
resistance.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Comprehensive excellent review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370557/
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka